AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00556439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept
Description: Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept.
Study NCT00556439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo abatacept infusions will be given monthly after random assignment at Month 3.
Study NCT04328896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM-Tele-monitoring
Description: Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis
Study NCT00804050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion A: rEPO
Description: rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
Study NCT00804050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B Infusion rEPO combined with vitamins pills
Description: rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
Study NCT00562432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Plexisyl-AF
Description: Plexisyl-AF implants
Study NCT00562432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plexisyl-AF
Description: Plexisyl-AF implants
Study NCT00562432 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Treatment
Description: CABG without the experimental treatment
Study NCT00701103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion
Study NCT01674153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-dialytic exercise
Description: Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
Study NCT03902132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability exercises group
Description: Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
Study NCT03902132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional low back physical therapy group
Description: The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
Study NCT03382730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chlorhexidine Mouth Rinse
Description: Oral chlorhexidine gluconate oral rinse
Study NCT03382730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Mouth Rinse De-Adoption
Description: Multifaceted education and audit/feedback.
Study NCT02778659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
Study NCT03402282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: upper rectal artery embolization with coils
Study NCT03402282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical repair
Description: surgical repair through the classic technique (Milligan and Morgan technique)
Study NCT01674192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: single dose of 2 mg prucalopride
Study NCT03470311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: 30mg in 1mL pre-filled syringe
Study NCT03470311 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo (1mL) in pre-filled syringe
Study NCT03091426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan 1%
Study NCT03091426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan 1.75%
Study NCT03091426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan 2.5%
Study NCT02760992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Baclofen
Description: Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
Study NCT02760992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Baclofen
Description: 10 mg tablet
Study NCT03407235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computerized Laparoscopic Trainer
Description: Gold standard laparoscopic trainer using simulated computerized equipment.
Study NCT03407235 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Box trainer with eye patch
Description: Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
Study NCT01706237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexisvision shield
Description: A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
Study NCT02858492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg
Description: GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
Study NCT02858492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
Study NCT01789827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01789827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
Study NCT01789827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Description: Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
Study NCT01050608 — intervention group
Intervention type: DEVICE
Intervention: Body worn alcohol gel dispenser
Description: Records hand hygiene events of provider and tabulates on the group level.
Study NCT01050608 — intervention group
Intervention type: DRUG
Intervention: 62% ethanol based hand cleanser
Description: CDC based guidelines with regard to utilization in the health care environment the nest
Study NCT01050608 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational component with regard to teaching CDC guidelines
Description: 12 minute education prior to deploying device for all providers.
Study NCT01050608 — intervention group
Intervention type: BEHAVIORAL
Intervention: Provider and group feedback
Description: Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
Study NCT01381250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
Study NCT02359747 — intervention group
Intervention type: GENETIC
Intervention: Polymerase Chain Reaction and Whole Genome Amplification
Description: Polymerase Chain Reaction and Whole Genome Amplification
Study NCT00796679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
Study NCT00796679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paricalcitol
Description: oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
Study NCT00686075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 1
Description: Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 1
Description: Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 2
Description: Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 2
Description: Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 3
Description: Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 3
Description: Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 4
Description: Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 4
Description: Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 5
Description: Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT00686075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 5
Description: Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Study NCT03457467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
Study NCT03457467 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
Study NCT03250559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: Endoscopic kidney stone extraction technique.
Study NCT03254381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
Study NCT03254381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Tone Training
Description: Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
Study NCT03107312 — intervention group
Intervention type: PROCEDURE
Intervention: Single blood sample collection
Description: Collection of single blood sample of 10 ml volume by venepuncture
Study NCT00574912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
Study NCT00574912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 0.5 u/kg body wt SC
Description: 8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
Study NCT00574912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 1.0 u/kg body wt SC
Study NCT00574912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 1.5 u/kg body wt SC
Study NCT00574912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 2.0 u/kg body wt SC
Study NCT02838654 — intervention group
Intervention type: PROCEDURE
Intervention: cervical epidural injection
Description: sensitivity, specificity, positive predictive value, negative predictive value
Study NCT00589329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin and metronidazole (antibiotics)
Description: Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days
Study NCT00589329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and pill placebo
Study NCT04180163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab solution, SC
Study NCT01163630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole/ASA Fixed Dose Combination (FDC)
Description: esomeprazole 20 mg/ASA 81 mg oral capsule
Study NCT02903992 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Dual-energy X-ray absorptiometry (DXA)
Description: Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
Study NCT02132637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SQ
Study NCT02132637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SQ
Study NCT04328857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pseudoelastic orthosis
Description: The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
Study NCT00806286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS7017 tablets
Description: CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
Study NCT00806286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
Study NCT00806286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
Study NCT00806286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
Study NCT00806286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
Study NCT00806286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets matching CS-7017 tablets
Study NCT02395952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium
Description: frequent topical lubrication with artificial tears
Study NCT02395952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Bandage Contact Lens
Study NCT02395952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambiodisk
Study NCT02395952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prokera
Study NCT01545661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum induction
Description: Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
Study NCT01545661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard routine expectorated sputum
Description: Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
Study NCT00845819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEGF + povidone iodine, chlorhexidine, & nystatin
Description: Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) \& nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva.
Study NCT00845819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + povidone iodine, chlorhexidine, & nystatin
Description: Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva.
Study NCT04727814 — intervention group
Intervention type: OTHER
Intervention: Computer-aided detection system overlaid colonoscopy videos analysis
Description: Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
Study NCT00289536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: 15 IU/kg rAHF-PFM
Study NCT00289536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: 30 IU/kg rAHF-PFM
Study NCT00289536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: 50 IU/kg rAHF-PFM